Insulet Corporation (NASDAQ:PODD) is among the 10 High Growth S&P 500 Stocks to Buy Now. Truist on February 19, 2026, lowered ...

Insulet’s modeled fair value has been trimmed from US$369.64 to US$354.40, signaling a more measured view of upside in the current setup. That shift lines up with Street research that is resetting ...

Insulet Stock: why GLP-1 fears are overblown, with growth driven by Europe/MENA expansion. Read here for a detailed analysis on PODD stock.

Insulet Corporation (NASDAQ:PODD) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 4, Stifel lowered its price target on Insulet Corporation (NASDAQ:PODD) ...

Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround ...

The prices paid for the shares ranged from $238.55 to $241.56. Following the transaction, McEvoy directly owns 13,916 shares of Insulet. According to InvestingPro analysis, the stock appears ...

Shares of Insulet Corp. PODD rallied 3.10% to $249.38 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.04% to 6,837.75 and ...

A Billionaire Just Bet Big On This AI Stock. Should Investors Follow Suit? (The Motley Fool) ...

On Sunday, March 15, First Congregational Church’s Vestry Adult Choir and Jubilate Bell Choir will present their annual spring concert, “Music For Your Soul,” at 4 p.m. in the church’s ...

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in ...

Chinese partner Tonghua Dongbao completed BioChaperone® Lispro Phase 3 program with positive data on people with type 1 diabetes, completing the positive results obtained on type 2 diabetesContinued ...